Research and Markets: Global Contrave (Obesity) Market 2014 - Forecast and Opportunities to 2022

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/3gnwbc/contrave) has announced the addition of the "Contrave (Obesity) - Forecast and Market Analysis to 2022" report to their offering.

After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients.

Contrave is an investigational medication being evaluated for weight loss by San Diego, California-based Orexigen Therapeutics in partnership with Takeda Pharmaceuticals in Osaka, Japan. Takeda has already paid a $50m upfront payment to Orexigen and will be eligible to receive up to $1 billion for achieving certain regulatory and sales milestones. Takeda has obtained exclusive marketing rights for the markets in the United States, Canada and Mexico, while Orexigen maintains the right to co-promote Contrave in the US.

Scope

  • Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Contrave including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Contrave for the top eight countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil and Canada

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Opportunity and Unmet Need

7 Pipeline Assessment

8 Contrave

9 Appendix

For more information visit http://www.researchandmarkets.com/research/3gnwbc/contrave

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals